Get the Stockscreener App
8.75
12.15%
-1.21
Candel Therapeutics Inc stock is traded at $8.75, with a volume of 4.82M.
It is down -12.15% in the last 24 hours and up +119.85% over the past month.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
See More
Previous Close:
$9.96
Open:
$9.14
24h Volume:
4.82M
Relative Volume:
1.56
Market Cap:
$389.16M
Revenue:
$124.00K
Net Income/Loss:
$-49.99M
P/E Ratio:
-7.8829
EPS:
-1.11
Net Cash Flow:
$-31.03M
1W Performance:
+29.63%
1M Performance:
+119.85%
6M Performance:
+46.32%
1Y Performance:
+681.25%
1-Day Range:
$8.25
$9.9996
1-Week Range:
$5.90
$10.38
52-Week Range:
$1.06
$14.60
Candel Therapeutics Inc Stock (CADL) Company Profile
Name
Candel Therapeutics Inc
Sector
Industry
Phone
617-916-5445
Address
117 KENDRICK STREET, NEEDHAM
Compare CADL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
8.75 | 389.16M | 124.00K | -49.99M | -31.03M | -1.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-22 | Initiated | H.C. Wainwright | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Aug-23-21 | Initiated | Credit Suisse | Outperform |
| Aug-23-21 | Initiated | Jefferies | Buy |
| Aug-23-21 | Initiated | UBS | Buy |
Candel Therapeutics Inc Stock (CADL) Latest News
Research Analysts Set Expectations for CADL FY2024 Earnings - Defense World
FY2024 Earnings Forecast for CADL Issued By HC Wainwright - MarketBeat
Candel Therapeutics Shares Leap on Chairman Purchase - MarketWatch
Candel Therapeutics rides high on promising Phase 3 data, funding boost - Proactive Investors UK
Candel Therapeutics Inc call volume above normal and directionally bullish - TipRanks
Insider Buying: Candel Therapeutics, Inc. (NASDAQ:CADL) Director Purchases 1,250,000 Shares of Stock - MarketBeat
Candel Therapeutics stock upgraded as CAN-2409 delivers in prostate cancer trial - Investing.com
Candel Therapeutics aims to transform cancer outcomes - Proactive financial news
HC Wainwright Reiterates Buy Rating for Candel Therapeutics (NASDAQ:CADL) - MarketBeat
Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares - The Manila Times
Candel Therapeutics raises $92M in public offering following prostate cancer trial success - Proactive financial news
StockWatch: Q32 Shares Crater 85% as Investors, Analysts Sour on Trial Results - Genetic Engineering & Biotechnology News
Candel Therapeutics announces $80 million proposed public offering - MSN
Candel Therapeutics (NASDAQ:CADL) Stock Quotes, Forecast and News Summary - Benzinga
SEC Form 424B5 filed by Candel Therapeutics Inc. - Quantisnow
Candel’s Phase III Prostate Cancer Win Comes In the Nick Of Time - Citeline News & Insights
What's Going On With Candel Therapeutics Shares Friday? - Benzinga
Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Candel Therapeutics unveils $80M public offering - Proactive Investors Australia
Candel Therapeutics stock drops after pricing public offering By Investing.com - Investing.com Canada
Candel Therapeutics stock drops after pricing public offering - Investing.com
CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary Goal - MSN
Candel Therapeutics Shares Fall Premarket After Public Offering - MarketWatch
Candel Therapeutics Announces Positive Phase 3 Trial Results for CAN-2409 in Prostate Cancer - Defense World
Candel Therapeutics Target of Unusually Large Options Trading (NASDAQ:CADL) - Defense World
Candel Therapeutics Prices of Public Offering - citybiz
Candel Therapeutics Launches $80M Public Offering to Advance Prostate Cancer Treatment Pipeline - StockTitan
Candel Therapeutics Announces Pricing of Public Offering - The Manila Times
After-hours movers: Broadcom, Costco, EVgo, Candel Therapeutics By Investing.com - Investing.com Canada
Candel Therapeutics slides after launching $80 mln stock offering - XM
Candel Therapeutics Announces $80 Million Proposed Public Offering - The Manila Times
After-hours movers: Broadcom, Costco, EVgo, Candel Therapeutics - Investing.com
Candel Therapeutics Shares Are Up Today: What's Going On? - Benzinga
Candel Therapeutics stock soars to 52-week high of $14.47 By Investing.com - Investing.com Nigeria
Gamestop, Adobe, Meta, Candel Therapeutics, And Tesla: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Candel Therapeutics Stock More Than Doubles After Strong Prostate Cancer Trial Results: Retail Goes Wild - MSN
Candel leads biotech gainers amid wave of data readouts - BioCentury
Candel stock rockets on Phase 3 results for CAN-2409 (update) - MSN
Candel Skyrockets 68% On A Potential First-In-20-Years Cancer Drug - Yahoo! Voices
Biotech Rockets 68% On A Potential First-In-Decades Drug - Investor's Business Daily
Candel Therapeutics Prostate Cancer Therapy Shows Promise - Yahoo Finance
Crude Oil Jumps 2%; Macy's Lowers Earnings Forecast - Benzinga
Candel stock rockets 130% on Phase 3 results for CAN-2409 - MSN
Candel Therapeutics: Surprising Win Puts Potential Drug Approval In Sight (CADL) - Seeking Alpha
Wick-ed good phase III prostate cancer data light up Candel - BioWorld Online
Candel Therapeutics Stock Surges Over 100%Here's Why - AOL
U.S. STOCKS Candel Therapeutics, Broadcom, Reddit - XM
Candel's cancer therapy meets late-stage trial goal, shares soar - Reuters
Biotech Stock Hits 3-Year Highs on Trial Results - Schaeffers Research
Nasdaq Surges Over 1%; US Inflation Rises In-Line With Expectations - Benzinga
Candel Therapeutics stock up 172% after Phase III prostate cancer success - Yahoo Finance
Candel Therapeutics Inc Stock (CADL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Candel Therapeutics Inc Stock (CADL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Tyagarajan Seshu | Chief Technology Officer |
Nov 29 '24 |
Sale |
4.56 |
20,392 |
92,898 |
125,657 |
| Tak Paul Peter | Chief Executive Officer |
Nov 29 '24 |
Sale |
4.56 |
48,847 |
222,527 |
294,788 |
| Nichols William Garrett | Chief Medical Officer |
Nov 29 '24 |
Sale |
4.56 |
13,935 |
63,482 |
100,547 |
| Barone Francesca | Chief Scientific Officer |
Nov 29 '24 |
Sale |
4.56 |
22,081 |
100,592 |
137,880 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):